Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pliant Therapeutics, Inc.
National Cancer Institute (NCI)
Travera Inc
Ohio State University
Hoffmann-La Roche
Arvinas Inc.
Jonsson Comprehensive Cancer Center
xCures
University of Pittsburgh
West China Hospital
Massive Bio, Inc.
Actym Therapeutics, Inc.
Toray Industries, Inc
Eli Lilly and Company